Intriguingly, glucose-lowering drugs, especially those with proven cardiovascular beneficial agents such as GLP-1 receptor agonists and sodium-glucose co-transporter inhibitors, have been shown to exert direct anticoagulation effects in patients with diabetes, thus allowing new strategies in the treatment of diabetic comorbidities [80]. The gene discussed is GLP1R; the disease is diabetes mellitus.